PARK7 and acute myeloid leukemia: We found that the survival rates of AML patients in GSE12417 and TCGA-LAML cohorts were significantly different among DYNC1H1+CD8+ T−C2, DYNC1H1+NK-C3, DYNLL1+Mac-C1, PAPK7+Mac-C4, PARK7+NK-C4, TUBA1A+Mac-C3, TUBA1B+CD8+ T−C1, UBE2N+CD8+ T−C4, UBE2N+NK-C1, UBE2V1+CD8+ T−C3, UBE2V1+Mac-C2, and UBE2V1+NK-C2 (Figure 5C).